sansrosa articles ↓

The dermatology news sheet Dermatology Times has published an item to their web site about the emerging use of oxymetazoline to treat the redness and flushing associated with rosacea. This article draws from the Nov. 2007 paper that introduced us to the possibility of treating rosacea with oxymetazoline. We also know from …

The Clinical Trial register is showing details for the bio-availabilty trial for COL-118/Sansrosa. This Phase 2 trial aims to compare the amount of the active ingredient that is bio-available when the newly formulated gel is used on rosacea skin, and when used as eye drops.

This announcement appears to be the extra trial asked for by the FDA who are concerned that …

According to the just published earnings call, Collagenex have been asked to undertake a additional Phase 2 study before commencing Phase 3. These additional studies will take several months, delaying the start of Phase 3. Collagenex are still hopeful of commencing Phase 3 studies some time before the end of 2008.

These additional studies are to confirm that the diseased rosacea skin does not …

Regarding another investor conference today, CEO Colin Stewart presented and most of the information was familiar. However, during the question period, an audience member asked about rebound flushing/redness during the Sansrosa / COL-118 trials. The following is what was said:

Man: “I realize that it’s an in-class, COL-118, it’s kind of difficult to work out the economics of the opportunity. Now, the fact …

This poster abstract is an update to the paper that was published in Archives of Dermatology in 2007 and was covered by Rosacea News as Sansrosa’s sister to enter redness race. This now expanded abstract suggests that oxymetazoline is effective for up to 6 hours after application and no side effects have been seen after 3 months usage. Oxymetazoline is a …